Reassessing the adrenomedullin scavenging function of ACKR3 in lymphatic endothelial cells.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 10 01 2023
accepted: 26 04 2023
medline: 1 6 2023
pubmed: 30 5 2023
entrez: 30 5 2023
Statut: epublish

Résumé

Atypical chemokine receptor 3 (ACKR3) is a scavenger of the chemokines CXCL11 and CXCL12 and of several opioid peptides. Additional evidence indicates that ACKR3 binds two other non-chemokine ligands, namely the peptide hormone adrenomedullin (AM) and derivatives of the proadrenomedullin N-terminal 20 peptide (PAMP). AM exhibits multiple functions in the cardiovascular system and is essential for embryonic lymphangiogenesis in mice. Interestingly, AM-overexpressing and ACKR3-deficient mouse embryos both display lymphatic hyperplasia. Moreover, in vitro evidence suggested that lymphatic endothelial cells (LECs), which express ACKR3, scavenge AM and thereby reduce AM-induced lymphangiogenic responses. Together, these observations have led to the conclusion that ACKR3-mediated AM scavenging by LECs serves to prevent overshooting AM-induced lymphangiogenesis and lymphatic hyperplasia. Here, we further investigated AM scavenging by ACKR3 in HEK293 cells and in human primary dermal LECs obtained from three different sources in vitro. LECs efficiently bound and scavenged fluorescent CXCL12 or a CXCL11/12 chimeric chemokine in an ACKR3-dependent manner. Conversely, addition of AM induced LEC proliferation but AM internalization was found to be independent of ACKR3. Similarly, ectopic expression of ACKR3 in HEK293 cells did not result in AM internalization, but the latter was avidly induced upon co-transfecting HEK293 cells with the canonical AM receptors, consisting of calcitonin receptor-like receptor (CALCRL) and receptor activity-modifying protein (RAMP)2 or RAMP3. Together, these findings indicate that ACKR3-dependent scavenging of AM by human LECs does not occur at ligand concentrations sufficient to trigger AM-induced responses mediated by canonical AM receptors.

Identifiants

pubmed: 37252916
doi: 10.1371/journal.pone.0285597
pii: PONE-D-23-00791
pmc: PMC10228790
doi:

Substances chimiques

Adrenomedullin 148498-78-6
Chemokine CXCL11 0
Receptors, Adrenomedullin 0
ACKR3 protein, human 0
Receptors, CXCR 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0285597

Informations de copyright

Copyright: © 2023 Sigmund et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Immunol. 2009 Sep 1;183(5):3204-11
pubmed: 19641136
Nature. 1998 May 28;393(6683):333-9
pubmed: 9620797
Peptides. 2001 Nov;22(11):1753-63
pubmed: 11754961
Dev Dyn. 2011 Feb;240(2):384-93
pubmed: 21246655
Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14759-64
pubmed: 17804806
Br J Pharmacol. 2013 Feb;168(4):822-34
pubmed: 22946657
Cytokine. 2018 Sep;109:17-23
pubmed: 29903572
Cell. 2008 Feb 8;132(3):463-73
pubmed: 18267076
J Biol Chem. 2000 Sep 22;275(38):29602-9
pubmed: 10882736
Nat Commun. 2017 Jan 18;8:14135
pubmed: 28098154
J Exp Med. 2011 Feb 14;208(2):327-39
pubmed: 21300915
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24093-24099
pubmed: 31712427
Nat Commun. 2021 Feb 10;12(1):925
pubmed: 33568674
Front Immunol. 2019 Apr 12;10:518
pubmed: 31105685
Br J Pharmacol. 2018 May;175(9):1419-1438
pubmed: 29272550
J Exp Med. 2006 Sep 4;203(9):2201-13
pubmed: 16940167
J Exp Med. 1998 Jun 15;187(12):2009-21
pubmed: 9625760
Biochem Biophys Res Commun. 1995 Dec 26;217(3):832-8
pubmed: 8554605
Oncogene. 2010 Aug 12;29(32):4599-610
pubmed: 20531309
Genesis. 2008 May;46(5):235-45
pubmed: 18442043
Genes Dev. 2017 Aug 15;31(16):1615-1634
pubmed: 28947496
Peptides. 2020 Sep;131:170347
pubmed: 32569606
J Leukoc Biol. 2018 Aug;104(2):391-400
pubmed: 29601107
Biochem Biophys Res Commun. 2005 May 20;330(4):1146-52
pubmed: 15823563
Front Immunol. 2016 Jun 10;7:224
pubmed: 27375622
J Immunol. 2006 Feb 15;176(4):2197-207
pubmed: 16455976
Nat Commun. 2020 Jun 19;11(1):3033
pubmed: 32561830
Development. 2021 Jun 1;148(11):
pubmed: 34080610
J Immunol. 2010 Nov 1;185(9):5130-9
pubmed: 20889540
Hypertens Res. 2003 Feb;26 Suppl:S93-8
pubmed: 12630817
J Pept Sci. 2015 Dec;21(12):905-12
pubmed: 26767744
Front Pharmacol. 2018 Jun 21;9:641
pubmed: 29977203
Peptides. 2008 Dec;29(12):2243-9
pubmed: 18929609
Cell. 2013 Dec 5;155(6):1323-36
pubmed: 24315101
PLoS One. 2021 Apr 15;16(4):e0249068
pubmed: 33857173
J Mol Cell Cardiol. 2014 Dec;77:73-85
pubmed: 25264174
Cardiovasc Res. 2008 Dec 1;80(3):339-45
pubmed: 18708640
J Biol Chem. 2005 Oct 21;280(42):35760-6
pubmed: 16107333
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):148-160
pubmed: 26705849
Biochem Biophys Res Commun. 1993 Jul 30;194(2):720-5
pubmed: 7688224
J Clin Invest. 2008 Jan;118(1):40-50
pubmed: 18097475
ACS Pharmacol Transl Sci. 2021 Mar 22;4(2):813-823
pubmed: 33860204
Dev Cell. 2014 Sep 8;30(5):528-40
pubmed: 25203207
Br J Pharmacol. 2013 Feb;168(3):644-57
pubmed: 22946511

Auteurs

Elena C Sigmund (EC)

Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.

Aline Bauer (A)

Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.

Barbara D Jakobs (BD)

Biotechnology Institute Thurgau (BITg), University of Konstanz, Kreuzlingen, Switzerland.

Hazal Tatliadim (H)

Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.

Carlotta Tacconi (C)

Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.

Marcus Thelen (M)

Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana, Bellinzona, Switzerland.

Daniel F Legler (DF)

Biotechnology Institute Thurgau (BITg), University of Konstanz, Kreuzlingen, Switzerland.
Theodor Kocher Institute, University of Bern, Bern, Switzerland.

Cornelia Halin (C)

Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH